ANTHEM

** Brokerage BOBCaps initiates coverage on India's Anthem Biosciences ANTH.NS with "buy" rating, sets PT at 835 rupees

** Shares of ANTH down 1.5% to 653 rupees amid broader market downturn; Nifty 50 .NSEI down 2%

** Brokerage says co has gamut of innovative modalities

** Co's industry-high margin is expected to sustain, given the ramp up in peptides capacity, including backward integration and installing unit 4 for small molecules- BOBCaps

** Being one of the few backward-integrated peptide manufacturers, gives it cost edge over China competitors in GLP- BOBCaps

** Molecules sales are further likely to grow by $21.4 billion by CY29, indicating a CAGR of 13.5% CAGR from CY24-29- BOBCaps

** ANTH rated "strong buy" on avg by 6 analysts covering it; median PT at 772 rupees- data compiled by LSEG

** YTD, ANTH gains 2%

(Reporting by Komal Salecha in Bengaluru)

((Komal@thomsonreuters.com))

March 9 (Reuters) - Anthem BioSciences Ltd ANTH.NS:

• VIRIDITY TONE LLP SOLD 20.3 MILLION SHARES IN ANTHEM BIOSCIENCES VIA BULK DEAL - BSE DATA

• SBI MUTUAL FUND, HDFC MUTUAL FUND BUY SHARES IN ANTHEM BIOSCIENCES VIA BULK DEAL - BSE DATA

Further company coverage: ANTH.NS

((Reuters.Briefs@thomsonreuters.com;;))

Feb 5 (Reuters) - Anthem BioSciences Ltd ANTH.NS:

• DEC-QUARTER CONSOL PROFIT 928.2 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.23 BILLION RUPEES

Source text: ID:nBSE79mTmv

Further company coverage: ANTH.NS

((Reutersbriefs@thomsonreuters.com;))

** Nomura initiates coverage on Anthem Biosciences ANTH.NS with "buy," target price of 740 rupees - representing an 18% premium on last close

** Shares of ANTH rise as much as 3.6% to 651 rupees, last up ~1%

** Nomura says ANTH can sustain 17% growth in CY24–29, outpacing industry’s 13% growth in the contract research, development and manufacturing organisation segment

** Adds, co has a wider customer base and a strong "fee for service" strategy vs peers

** Anthem's stable leadership with employee attrition below peers has led strong operating performance with industry-leading profit margins and return ratios - Nomura

** Believes ANTH's key molecules' growth, new launches and capacity expansion are key positives for medium-term growth

** ANTH down 13% since listing on July 21

(Reporting by Manvi Pant)

((Manvi.Pant@thomsonreuters.com; +918447554364;))

** Shares of Anthem Biosciences ANTH.NS rise 7.6% to record high of 812 rupees

** Stock marks record high intraday pct gain since debut on July 21

** Pharma co posts nearly 65% y/y rise in June-quarter consol profit; rev from ops rises nearly 60% y/y

** ANTH gains 11% since market debut

(Reporting by Rudra Pratap Singh in Bengaluru)

((rudrapratap.singh@thomsonreuters.com))

** Shares of India's Anthem BioSciences ANTH.NS rise 27% in trading debut to 726 rupees; shares were sold in the 540 rupees to 570 rupees price range in IPO

** Pharma co notches valuation of 408 bln rupees ($4.73 bln)

** Co's $395 million IPO, which was only a sale of shares by existing stakeholders, was fully subscribed last week

** Co - one of the leading global players in contract drugmaking and research - has made a strong debut, enjoys a niche place in the segment and leads pack of players - Shivani Nyati, Head of Wealth at Swastika Investmart

($1 = 86.2690 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru)

((Hritam.Mukherjee@thomsonreuters.com;))